Provided by Tiger Trade Technology Pte. Ltd.

Tempus AI

58.74
-2.5400-4.14%
Post-market: 58.56-0.1800-0.31%19:58 EDT
Volume:5.50M
Turnover:326.12M
Market Cap:10.66B
PE:-40.97
High:61.11
Open:59.87
Low:58.02
Close:61.28
52wk High:104.32
52wk Low:40.77
Shares:181.56M
Float Shares:115.00M
Volume Ratio:1.02
T/O Rate:4.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.4337
EPS(LYR):-1.4100
ROE:-67.44%
ROA:-8.55%
PB:23.97
PE(LYR):-41.66

Loading ...

AI Software Shares Fall. Tempus AI Sinks 9%; ServiceNow Down over 4%; Braze, SoundHound AI, Docusign, BigBear.ai Down over 2%

Tiger Newspress
·
Jul 20

Personalis to be acquired by Tempus AI in merger

TIPRANKS
·
Jul 20

Movement Alert|Tempus AI Falls 6.56% in Regular Trading, $1.5 Billion Acquisition of Personalis Sparks Market Concerns

Market Focus
·
Jul 20

Tempus AI Shares Down 6.4%

THOMSON REUTERS
·
Jul 20

Tempus Publishes Investor Deck on Planned Personalis Acquisition to Expand MRD Testing Platform

Reuters
·
Jul 20

Sector Update: Healthcare

MT Newswires Live
·
Jul 20

Tempus AI Falls 8% in Pre-Market Trading, Acquisition of Personalis Sparks Market Concerns Over Cash Deployment

Market Focus
·
Jul 20

Tempus AI Shares Fall 8.5% Premarket After Co to Acquire Personalis in $1.5 Bln Deal

THOMSON REUTERS
·
Jul 20

Tempus to Acquire Personalis for $1.5 Billion

Reuters
·
Jul 20

Tempus AI to acquire Personalis for $16.25 per share

TIPRANKS
·
Jul 20

Tempus AI Agrees to Buy Personalis for USD 16.25 Per Share in USD 1.5 Billion Deal

Reuters
·
Jul 20

Tempus AI Inc - Maximum Exchange Ratio Set at 0.3356 Tempus AI Shares Per Personalis Share

THOMSON REUTERS
·
Jul 20

Tempus - Consideration Structured as 100% Stock, Cash Option Capped at 50%

THOMSON REUTERS
·
Jul 20

Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (mrd) into Its Ai-enabled Precision Oncology Platform

THOMSON REUTERS
·
Jul 20

Tempus AI Inc - Cash Consideration Will be Financed with Cash on Hand and Borrowings Under Company's Then Existing Credit Facilities

THOMSON REUTERS
·
Jul 20

Dimon Warns AI Risks

AI Industry Frontlines
·
Jul 17

How Do Tempus AI’s (TEM) NHS Prostate Results Shape Its Clinical Credibility Narrative?

Simply Wall St.
·
Jul 17

AI Trading Has Become a 'Rubber Band,' Goldman Sachs Top Trader: The Question is 'When Will It Snap'

AI Industry Frontlines
·
Jul 17

AI Market Outlook; The Era Of Risk-Free Gains Has Come To An End

AI Industry Frontlines
·
Jul 17

Movement Alert|Tempus AI Falls 5.17% in Regular Trading, Partnership Termination and Executive Share Reduction Continue to Weigh on Stock

Market Focus
·
Jul 17